NASDAQ: DYNDyne Therapeutics Inc Stock Ownership - Who owns Dyne Therapeutics?
Insider buying vs selling
Have Dyne Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Brian S. Posner | Director | 2026-10-02 | 2,500 | $16.00 | $40.00kBuy |
| Johanna Friedlnaderer | CCO | 2026-09-08 | 185 | $18.88 | $3.49kSell |
| John Cox | CEO;Pres | 2026-09-08 | 5,658 | $18.88 | $106.82kSell |
| Douglas Kerr | Med | 2026-09-08 | 1,290 | $18.88 | $24.36kSell |
| Johanna Friedlnaderer | CCO | 2026-09-04 | 900 | $24.35 | $21.92kSell |
| Douglas Kerr | Med | 2026-09-04 | 3,745 | $24.35 | $91.19kSell |
| Jason P. Rhodes | Director | 2026-08-14 | 322,465 | $25.00 | $8.06MSell |
| Jason P. Rhodes | Director | 2026-08-14 | 1,359,674 | $25.00 | $33.99MSell |
| Jason P. Rhodes | Director | 2026-08-14 | 478,377 | $25.00 | $11.96MSell |
| Jason P. Rhodes | Director | 2026-08-13 | 268,354 | $26.20 | $7.03MSell |
DYN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when DYN insiders and whales buy or sell their stock.
DYN Shareholders
What type of owners hold Dyne Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Dirk Kersten | 3.98% | 7,435,052 | $126.69M | Insider |
| Atlas Venture Fund XI LP | 3.51% | 6,562,578 | $111.83M | Insider |
| Forbion Capital Fund IV Cooperatief Ua | 3.28% | 6,131,079 | $104.47M | Insider |
| VV Manager II LLC | 1.59% | 2,960,046 | $50.44M | Insider |
| Ra Capital Management LP | 1.50% | 2,805,045 | $47.80M | Insider |
| Atlas Venture Opportunity Fund II LP | 1.36% | 2,543,366 | $43.34M | Insider |
| Atlas Venture Opportunity Fund I LP | 1.23% | 2,306,079 | $39.30M | Insider |
| Wellington Biomedical Innovation Master Investors Cayman I LP | 0.86% | 1,608,785 | $27.41M | Insider |
| Logos Global Management LP | 0.81% | 1,504,392 | $25.63M | Insider |
| Cureduchenne Ventures LLC | 0.32% | 602,972 | $10.27M | Insider |
DYN vs Biotech Stocks
Dyne Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.